The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: A case for continuous surveillance

Pediatric Infectious Disease Journal

Volumn 31, Issue 3, 2012, Pages 228-234

  Ampofo, Krow ^a   Pavia, Andrew T ^a   Chris, Stockmann ^a   Hersh, Adam L ^a   Bender, Jeffrey M ^b   Blaschke, Anne J ^a   Weng, Hsin Yi Cindy ^a   Korgenski, Kent E ^a,c   Daly, Judy ^a,c   Mason, Edward O ^d   Byington, Carrie L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

invasive pneumococcal disease; PCV13; PCV7; serotype; Streptococcus pneumoniae

Indexed keywords

CEFOTAXIME; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CHILD; DISEASE SURVEILLANCE; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MENINGITIS; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, PNEUMOCOCCAL; OSTEOARTHRITIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 84857639578     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823dcc72     Document Type: Article

References (40)

1. Statistics and Surveillance: Immunization Coverage in the U.S. 2009. Available at: http://www.cdc.gov/vaccines/stats-surv/imz-coverage.htm# nis. Accessed May 13, 2009.
2. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-1354. (Pubitemid 351412007)
3. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis. 2005;41: 21-29. (Pubitemid 40863739)
4. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792. (Pubitemid 46658647)
5. Eastham KM, Freeman R, Kearns AM, et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax. 2004;59:522-525. (Pubitemid 38797527)
6. Obando I, Arroyo LA, Sanchez-Tatay D, et al. Molecular typing of pneumococci causing parapneumonic empyema in Spanish children using multilocus sequence typing directly on pleural fluid samples. Pediatr Infect Dis J. 2006;25:962-963. (Pubitemid 44510606)
7. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet. 2000;356: 1210-1211.
8. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. Morb Mortal Wkly Rep. 2010;59:258-261.
9. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2000; 49(RR-9):1-38.
10. Clinical and Laboratory Standards Institute/NCCLS 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI/NCCLS document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute.
11. Techasaensiri C, Messina AF, Katz K, et al. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J. 2010;29:294-300.
12. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746. (Pubitemid 36514704)
13. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2.
14. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006;193:1487-1494. (Pubitemid 43794576)
15. Ampofo K, Pavia AT, Stockmann C, et al. Evolution of the epidemiology of pneumococcal disease among Utah children through the vaccine era. Pediatr Infect Dis J. 2011;30:1100-1103.
16. Chibuk TK, Robinson JL, Hartfield DS. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with pneumococcal conjugate vaccine (PCV7). Eur J Pediatr. 2010;169:1123-1128.
17. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125:26-33.
18. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502. (Pubitemid 44634693)
19. Park SY, Van Beneden CA, Pilishvili T, et al. Invasive pneumococcal infections among vaccinated children in the United States. J Pediatr. 2010;156:478-483.e2.
20. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348. (Pubitemid 37186212)
21. Rosen JB, Thomas AR, Lexau CA, et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011;53:137-143.
22. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256.
23. Centers for Disease Control and Prevention. Emergence of antimicrobialresistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. Morb Mortal Wkly Rep. 2007;56:1077-1080.
24. Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988-1995. (Pubitemid 41681898)
25. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016-1027. (Pubitemid 351590031)
26. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125:429-436.
27. Jacobs MR, Good CE, Bajaksouzian S, et al. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis. 2008;47:1388-1395.
28. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46:1346-1352. (Pubitemid 351589931)
29. Muñoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182. (Pubitemid 351269154)
30. Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. 2006;25:250-254. (Pubitemid 43379067)
31. Obando I, Munoz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis. 2008;14:1390-1397.
32. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
33. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004;39:641-648. (Pubitemid 39180434)
34. Dagan R, Givon-Lavi N, Zamir O, et al. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J. 2003;22:532-540.
35. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302: 758-766.
36. Beall BW, Gertz RE, Hulkower RL, et al. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360-1368.
37. Tarrago D, Aguilar L, Garcia R, et al. Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008. Antimicrob Agents Chemother. 2011;55:2297-2302.
38. Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother. 2009;63:511-519.
39. Temime L, Boelle PY, Valleron AJ, et al. Penicillin-resistant pneumococcal meningitis: high antibiotic exposure impedes new vaccine protection. Epidemiol Infect. 2005;133:493-501. (Pubitemid 40867686)
40. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30:289-294.